Everolimus improves progression-free survival for patients with rare pancreatic cancer

Houston - In an international Phase III randomised study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumours (pNET), according to researchers from The University of Texas MD Anderson Cancer Centre...

Read the whole article on

More from